Full-Time
Confirmed live in the last 24 hours
Biotech solutions for protein expression and purification
$220k - $270kAnnually
Senior, Expert
Vancouver, WA, USA
Hybrid option 2-3 days/week; consistent on-site presence required.
You match the following Absci's candidate preferences
Employers are more likely to interview you if you match these preferences:
AbSci improves protein expression and biomanufacturing in the biotech industry with its advanced platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system for precise control over protein production. Its standout product, SoluPure, is a chromatography-free purification method that simplifies and speeds up the protein purification process. AbSci sets itself apart from competitors by offering proprietary technologies that enhance drug discovery and manufacturing, aiming to replace traditional methods with more efficient solutions. The company's goal is to introduce efficiencies and cost savings to the biotech industry, transforming the production of biologics.
Company Size
51-200
Company Stage
IPO
Total Funding
$221.7M
Headquarters
Vancouver, Washington
Founded
2011
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Company Equity
Employee Stock Purchase Plan
VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.” Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids
Absci Founder & CEO Sean McClain will discuss the strategic partnership at the 43rd Annual J.P.Morgan Healthcare Conference on Wednesday January 15th at 4:30pm PT.
AMD has invested $20 million in Absci Corp., an AI-driven drug discovery company. The partnership will see Absci shift some workloads to AMD's Instinct AI processors, enhancing its research capabilities. Absci will use the investment to improve its AI models and collaborate with AMD on developing new hardware and software for healthcare, focusing on drug discovery advancements.
VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) - Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct(TM) accelerators and ROCm(TM) software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models.
Absci (NASDAQ: ABSI), a leader in AI-driven drug discovery, secured a $20 million strategic investment from Advanced Micro Devices (AMD).